REaCT
REthinking Clinical Trials

REaCT-VA HER2 negative

REaCT-VA HER2 negative	Peripheral vein access vs. insertion of a PICC central line for breast cancer patients receiving adjuvant HER2 negative chemotherapy Principal Investigator(s): Dr. Mark Clemons
ClinicalTrials.gov: NCT02688998
It is clear that several factors affect the likelihood a patient will receive a central line for chemotherapy, including: the different durations of commonly used chemotherapy regimens; whether or not the regimen includes an anthracycline; access to services for insertion of devices; patient preference; the ability of the Registered Nurse to locate and cannulate veins for peripheral access and physician practice.  Determining the optimal vascular access strategy remains an important medical issue for patients, nurses, physicians and society. This study is complete.
Sites: Cancer Centre of Southeastern Ontario (Kingston) The Ottawa Hospital
Tags: Early stage Breast Cancer
Publications: Systematic Review: Optimal vascular access strategies for patients receiving chemotherapy for early stage breast cancer: a systematic review. Robinson et al, 2018. PMID: 29974358 Surveys: Optimising vascular access for patients receiving intravenous systemic therapy for early stage breast cancer – A survey of oncology nurses and physicians. Levasseur et al, 2018. PMID: 30111975 Perceptions around vascular access for intravenous systemic therapy and risk factors for lymphedema in early stage breast cancer – A patient survey. Levasseur et al, 2018. PMID: 30111976 Clinical Trial results: A multicentre, randomized pilot trial comparing vascular access strategies for early stage breast cancer patients receiving non-trastuzumab containing chemotherapy. Robinson et al, 2019. PMID: 31392518